发明公开
- 专利标题： TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS
- 专利标题（中）： TROPOMYOSIN-RELATED KINASE（TRK）抑制剂
-
申请号： EP14824251.4申请日： 2014-12-10
-
公开(公告)号： EP3080108A1公开(公告)日： 2016-10-19
- 发明人: KANE, John L., Jr. , MATTHEWS, Gloria , METZ, Markus , KOTHE, Michael , LIU, Jinyu , SCHOLTE, Andrew
- 申请人： Genzyme Corporation
- 申请人地址： 500 Kendall Street Cambridge, MA 02142 US
- 专利权人： Genzyme Corporation
- 当前专利权人： Genzyme Corporation
- 当前专利权人地址： 500 Kendall Street Cambridge, MA 02142 US
- 代理机构： Nony
- 优先权： US201361914128P 20131210; US201462040750P 20140822
- 国际公布： WO2015089139 20150618
- 主分类号： C07D413/14
- IPC分类号： C07D413/14 ; A61K31/4184 ; A61K31/437 ; C07F9/50 ; C07D403/04 ; C07D403/14 ; C07D417/14 ; C07D487/04 ; C07D487/08 ; C07D487/10 ; A61P35/00
摘要：
Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).
公开/授权文献
- EP3080108B1 TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS 公开/授权日：2020-10-07
信息查询
